冠心病心律失常患者应用美托洛尔治疗的临床疗效观察

Observation on clinical efficacy of metoprolol in the treatment of patients with coronary heart disease and arrhythmia

目的 评价冠心病心律失常患者采用美托洛尔治疗的临床疗效。方法 118例冠心病心律失常患者,根据双色球抽取法分为常态组与科研组,每组59例。常态组采用稳心颗粒单一用药治疗,科研组采用美托洛尔与稳心颗粒联合治疗。评价两组心功能指标及安全性。结果 用药后,科研组短时程平均RR间期标准差为(132.24±11.52)ms,连续50 ms的百分数为(16.06±2.65)%,连续RR间期差值均方根为(39.73±4.18)ms, 24 h RR平均间期标准差为(143.34±11.21)ms,均高于常态组的(119.67±10.21)ms、(12.12±2.39)%、(31.85±3.04)ms、(130.02±10.23)ms,差异有统计学意义(P<0.05)。用药后,科研组血浆粘度为(1.23±0.27)mPa·s,红细胞压积为(43.24±2.51)%,红细胞沉降率为(4.77±1.53)mm/h,红细胞聚集指数为(1.91±0.23),低于常规组的(1.78±0.46)mPa·s、(47.24±3.89)%、(8.07±1.23)mm/h、(2.46±0.38),差异有统计学意义(P<0.05)。用药后两组均未出现明显不良反应。结论 冠心病心律失常患者治疗中采用美托洛尔效果显著,能有效改善患者心功能指标,安全性较高,值得临床推荐使用。

Objective To evaluate the clinical efficacy of metoprolol in the treatment of patients with coronary heart disease and arrhythmia. Methods A total of 118 patients with coronary heart disease and arrhythmia were divided into the normal group and the research group according to the two-color ball extraction method, with 59 cases in each group. The normal group was treated with Wenxin Granules alone, while the research group was treated with metoprolol combined with Wenxin Granules. The cardiac function indexes and safety of the two groups were evaluated. Results After medication, the standard deviation of the short-term mean RR interval in the research group was(132.24±11.52) ms, the percentage of continuous 50 ms was(16.06±2.65)%, the root mean square of the continuous RR interval difference was(39.73±4.18) ms, and the standard deviation of the mean interval of 24 h RR was(143.34±11.21) ms, which were higher than(119.67±10.21) ms,(12.12±2.39)%,(31.85±3.04) ms, and(130.02±10.23) ms in the normal group, and the differences were all statistically significant(P<0.05). After medication, the plasma viscosity in the research group was(1.23±0.27) mPa·s, the hematocrit was(43.24±2.51)%, the erythrocyte sedimentation rate was(4.77±1.53) mm/h, and the erythrocyte aggregation index was(1.91±0.23), which were lower than(1.78±0.46) mPa·s,(47.24±3.89)%,(8.07±1.23) mm/h, and(2.46±0.38) in the normal group, and the differences were all statistically significant(P<0.05).No obvious adverse reactions occurred in both groups after treatment. Conclusion The effect of metoprolol in the treatment of arrhythmia of coronary heart disease is significant, and can effectively improve the index of cardiac function with high safety, which is worthy of clinical recommendation and application.